Reddit Posts
Mentions
This is a stocked heavily pumped by the countrydumb subreddit and there leader no_put. Hes heavily invested in it. Hes been harping about this stock 100x’ng for a long time. Kinda the ATYR cult over there lol
Yeah I am holding jan26 calls on IOVA. It’s basically worthless right now, so I figured I’d let it ride and hope for a miracle with that for now. That was $1k down the drain. But everything looks strong for ATYR at the moment. It will definitely be one of my best investments this year *if* it plays out.
Honestly I was split 50/50 on IOVA and ATYR but I sold all my IOVA rolled it over and then doubled down on ATYR. I might buy more if it cools off as long as I can keep my average below $4. I’m also on r/countrydumb
Damn I’m jealous. I topped out at about 1200 before it got above $4. My avg is 3.50. One of the guys on r/countrydumb got in I think around 2.50 and has about $1m invested. I’m so mad because I split investment between this and IOVA. Wish I would have gone all ATYR.
https://preview.redd.it/wrhmw8do2e5f1.jpeg?width=1290&format=pjpg&auto=webp&s=4caf1a53c3ac764731c364d599d76f996e5e6e98 I love me some ATYR
Not true. Current valuations are based on a single indication (SARC) whereas $ATYR is emerging as a platform play (e.g. SSC-ILD readout just this week). The pipeline is strong, and over 300 patents in play.
He’s not far off on the 80–85%, though I’d attribute that probability to a clean Phase 3 readout in Q3. I run a subreddit solely focused on $ATYR — one of the fastest-growing finance communities on Reddit right now — and I’ve spent the past 9 months doing deep, institutional-grade research on it. In my view, $ATYR is one of the most asymmetric biotech setups in the market today. → [r/ATYR_Alpha](https://www.reddit.com/r/ATYR_Alpha/s/2VvJAaZX87)
Still holding KULR from fall of 2024 and MVST. Also dabbling in ATYR, PDYN, and ELTP
The title of your article is catchy. Can we agree though that 100 bagger potential is hyperbolic nonsense. HC Wainwright the most bullish says seven bagger which even still is jaw dropping. From five per share to thirty five would be a huge move but 5 X 100 seems delusional. Would put the market cap at 50 billion. What do you think the highest market Cap for a company like this could be and what type of comparison for that valuation. The price multiple for SMMT summit theurapeuticals got extremely high so if ATYR gets that type of price multiple it could go over 35. And then also M&A potential with Big Pharma. All in all it appears to be an asymmetric risk. I have 15,000 shares.
I sold all my VOO in March along with most of my tech stocks that were hemorrhaging money. Currently, my largest stakes after cash are RNMBY, ATYR, and assorted gold (physical and funds) and a mining fund. I'm still holding COST and BRK-B, along with a handful of small stakes in some possible value gambles. I'm quite happy with my decision.
Why is everyone going crazy over ATYR? Someone explain if it’s really a 10 bagger or just another pump and dump biotech.
ATYR going insano style this week
Right, sorry what i meant was you overall spent 2M on ATYR (money which you got from growing 100k) Lol you "turned the $100k into $600 on stocks" sounds about right lol Awesome man
I keep hearing about this ATYR stock. What we thinking about it boys
No. I started with $100k and grew it. Turned the $100k into $600 on stocks, then bought $80k worth of ACHR options that hit for $2.1M, then rolled all that into ATYR and doubled it.
You’re late to ATYR if you buy in now. A good entry would have been 3 weeks ago when it was ~$3. It’s at it’s 52 week high right now.
ATYR and PDYN are some new dabblers. But I’m still stocking more of KULR and MVST as well
Balls deep on ATYR. I love stupid decisions
Not in June but there will be huge moves with ATYR by October. Still a good time to get in. Check it out and thank me later
Yes. Should be titled "Luggage sales." I found a good one here. The countrydumb by no_puts.... He goes by Tweedle. He was right about ATYR and provided DD. He went deep and could hit $10M+ on his gamble. I make money if I sell. I am being greedy on this one.
Yes. I still have 8,200 shares in traditional IRA All in on ATYR, Analysts average price target of $25 https://preview.redd.it/ub4tqzpjgq4f1.jpeg?width=1290&format=pjpg&auto=webp&s=23505ee729378ac0e4a87487b7ce5667ff55dd89
https://preview.redd.it/r95y7jqzfq4f1.jpeg?width=1290&format=pjpg&auto=webp&s=905d28b86f9379a9c4e634287625beed165d6f84 ATYR
Might be the last time I can post about ATYR in here. After tomorrow, no longer a penny stock 🤞
No. $2M big jump were ARCH $7 calls I paid a nickel for. Some YouTuber on Yummers made a funny video/documentary about it back in December. Profits from ACHR I rolled into ATYR
ATYR full port has been successful so far
Up for the week, yes. Mainly because ATYR went up 5% today while alllll the rest went red.
$ATYR, if the goal is EUR 1m this year.
ATYR. Still below $4 resistance, but we’ll see how long that lasts…
Welcome to the sector! Ask me any question, I’ll be happy to answer if I can. If you’re interested in my approach to analysis, drop by my community ATYR_Alpha and check it out. I follow $ATYR at the moment, but my forensic-level approach applies to all bio’s.
Got my money on ATYR fwiw
I’m looking to get into ATYR ..might now go up a lot until early October but should definitely spike up then
Catalyst is a little further out, but any opinions on ATYR?
Check out the sub /ATYR_Alpha for a seriously deep dive. The home page of sub /CountryDumb will give you the lite version. /CountryDumb community owns 5 million shares collectively.
Reminding friends to get ATYR while it’s still under $4. It’s starting to move, but institutional is slowing it down artificially while they try to load up. The move is to what they do. I’m full port already w/ $600k invested. Just wish I could buy more. Cheers 🍻
ATYR. But it won’t be a penny stock for long. Starting to rise this week on good news. I’m expecting $30 by end of year, $90 in 2026-27.
ATYR. But it won’t be a penny for long. Here’s the case for surpassing $30 this year, and $100 by 2028. https://www.reddit.com/r/ATYR_Alpha/s/jje0YQpSXz
Completely agree, stoked to be on the ride with you amigo! If you’re up $75k, you’ve got a lot in it. Is ATYR your biggest holding?
Keep holding ATYR. Already full port, otherwise I’d buy more. Now let’s moon 🚀
I’m all in on ATYR because 1. the risk of major loss is low at the current price, and 2. the likelihood of a large return is high. There are a lot of indicators you can look at to see if stocks are low in risk and high in potential for reward. A couple I focus on are: - analyst price targets (like to see 500% above current) - P/E (low for the industry) or if not yet profitable, then enough cash on hand to take the company to a catalyst event without having to raise money - insider holdings, are the people who work there buying the stock? There are a lot more, but just those three will filter out a lot of suboptimal investments pretty quick. Hope this helps!
Just jumped in on ATYR. Also risky as a single-asset biotech with no revenue, but feels like a better bet. Potential to 3x or more in a few months. Thanks for the tip!
Consider buying $ATYR. Best investment than IOVA
Sorry and no. Tweedle met with ATYR management. 3rd Qtr info was about ATYR.
Check out pennystock ATYR and the blog here at r /CountryDumb. The due diligence can be found in the many postings. I jumped in on IOVA at $2.90 a month ago. It is currently at $1.76. Earnings weren't great this past quarter so buyer beware. Some investors include Wayne Rothman and Blackrock.
ATYR at a good entry for a swing trade. Gonna load back up.
Thanks for the response—and I completely understand the instinct to push back on lofty valuation targets. But let’s walk through your points carefully because, respectfully, some key facts may shift the risk/reward framing. **1. “Valuation is not absurdly low—it reflects trial risk.”** True in principle—but the degree of discount here is extreme relative to peers with similar data maturity. - ATYR trades at a ~$300M market cap while entering **Q3 Phase 3 readout** for a rare disease with **zero FDA-approved competitors**. It has: - Statistically significant Phase 2a data (+180mL FVC, p = 0.035; 85% relapse reduction) *(ERJ Open Research, May 2025)*, - A fully enrolled, DSMB-validated 268-patient Phase 3 (EFZO-FIT) *(aTyr Corporate Update, May 2025)*, - A running FDA-sanctioned **Expanded Access Program** based on investigator demand *(aTyr Q1 2025 earnings)*, - **Orphan + Fast Track** designation from both FDA and EMA for sarcoidosis and SSc-ILD *(FDA/EMA designations via aTyr IR website)*. This is not a preclinical pipe dream. It’s a **de-risked, regulatory-aligned, pre-commercial setup**. By contrast, Arena ($6.7B), Receptos ($7.3B), and Karuna ($14B) all had Phase 2/3 immunology assets at time of takeout—but **none had the biological depth or platform optionality** that ATYR offers in fibrosis, ILD, and oncology *(comps: Pfizer, Celgene, BMS acquisition data)*. **2. “Weakish readout or delay would be a big issue as money runs out in Q4.”** Important concern—but it’s not accurate to say they’ll run out of money before the readout. - Cash balance as of Q1 2025 = **$78.8M** *(Q1 2025 10-Q filing)*, - Runway explicitly covers operations **through and beyond Phase 3 readout** in Q3 *(Q1 2025 earnings call)*. In addition, aTyr is eligible for additional milestone payments from their Japan partner **Kyorin**—with over **$155M in development and commercial milestones** remaining *(Kyorin partnership agreement via aTyr IR)*. **3. “The trial is just testing steroid reduction, not disease modification.”** This is a misunderstanding of both the **design** and **regulatory context**. Yes, the **primary endpoint is steroid reduction**—but: - That is **aligned with FDA guidance** and accepted as a valid clinical endpoint in sarcoidosis *(FDA/ATS/WASOG guidelines)*. - The trial also has **secondary endpoints** for **lung function (FVC), quality of life (KSQ-Lung)**, and **symptom burden** *(ClinicalTrials.gov EFZO-FIT entry)*. Importantly, the *prior* Phase 2a trial already showed **concurrent improvement** across all of these dimensions—even during a forced steroid taper: - +180mL FVC - 85% reduction in relapse - Better KSQ and biomarker profiles than placebo *(ERJ Open Research, 2025)* And this isn’t just internal data: it’s **peer-reviewed, published**, and was even selected for the **Best of CHEST 2024** conference *(CHEST 2024 Abstract Highlights)*. **4. “This isn’t a multi-billion platform. That’s retail hopium.”** Again, let’s look at the facts: - **Sarcoidosis** TAM = $1.6B–$2.3B *(DelveInsight and GlobalData reports)*, - **Systemic sclerosis-ILD** = high-mortality, no curative options. TAM easily exceeds $1B *(Science Translational Medicine 2025; ACR/NIH estimates)*, - **CTD-ILD, CHP** and other ILDs = follow-ons with demonstrated NRP2 macrophage involvement *(Science Translational Medicine 2025; aTyr pipeline)*, - **ATYR0101**: Anti-fibrotic fusion protein targeting LTBP1 → $3B+ across liver, kidney, and lung fibrosis *(aTyr pipeline briefing, 2024)*, - **ATYR2810**: Oncology bispecific targeting NRP2/VEGF-C → data presented at **AACR 2025** *(AACR 2025 Abstract Book)*. Together, this forms a **tRNA synthetase-derived immunobiology platform with over 200 granted patents** *(aTyr IP portfolio overview)*. **Bottom Line** There are always risks in biotech, but $ATYR is being valued like a Phase 1 single-pathway flyer. That simply doesn’t match the dataset, pipeline, or strategic positioning. - This is a **Phase 3 platform** with clean safety, validated mechanism (NRP2), and FDA-aligned endpoints. - It is trading at **1/10th–1/20th the valuation of peer takeouts** with similar or inferior data. - Float is **tightly held by institutions (~97% of float), short interest is 12%, and volume remains thin**—all preconditions for structural dislocation if results are clean. No hopium here—just asymmetric math and a very real shot at re-rating. Appreciate the skepticism—it sharpens the argument. But this setup is rare, and all the ingredients are on the table. Let’s see what happens.
Thank you for your kind words. I most definitely do not work for $ATYR. I enjoy forensic analysis in the pursuit of high conviction trades. My background is in quantitative finance and corporate strategy.
Do you work for ATYR? This is much appreciated, and all that is good about Reddit.
**Thanks for sharing your thoughts—there’s obviously value in discussing trial design concerns critically. That said, I believe several points in your comment fully deserve further clarification based on the EFZO-FIT trial design, published data, and best practices in steroid-sparing studies.** **1. Baseline Imbalance:** The claim that “the test groups were not identical at the start” doesn’t align with the published EFZO-FIT design (ATS 2024 abstract) or company disclosures. Patients were randomized across 85 global sites with strict eligibility criteria: biopsy-confirmed sarcoidosis ≥6 months, FVC ≥50%, KSQ-Lung ≤70, and baseline prednisone dose between 7.5–25 mg/day. The use of stratified randomization and exclusion of patients on >1 immunosuppressant minimized variability. In fact, EFZO-FIT is considered one of the *most rigorously designed placebo-controlled trials ever run in this indication*. **2. Confidence Intervals and Early-Phase Data:** Yes, the earlier Phase 1b/2a study (n=37) had overlapping confidence intervals between 5mg/kg and placebo on some endpoints—but this is typical in small early-phase trials. What mattered was that efzofitimod showed dose-dependent improvement in both **steroid reduction** and **patient-reported outcomes** (PROs), which led to 5mg/kg being selected for Phase 3. The EFZO-FIT trial (n=264+) is powered to resolve those CI overlaps and detect statistical significance. There have been *no DSMB stoppages or amendments*—a key signal that efficacy or futility thresholds weren’t breached early. **3. Steroid Tapering and Subjectivity:** You’re right: steroid-sparing studies can introduce subjectivity due to physician judgment. But EFZO-FIT minimizes this risk through: - Forced taper protocol: Patients tapered between Day 15–85, reducing variability. - Fixed baseline steroid range: All patients began on a standard 7.5–25 mg/day dose. - Blinded review and centralized protocols. Moreover, the trial triangulates steroid tapering with **objective measures** (FVC) and **validated PROs** (KSQ-Lung, SGRQ). So while subjectivity exists, the design incorporates safeguards to extract a clinically and statistically meaningful signal. **4. Signs of Efficacy Are Real—and Consistent:** In the earlier study, 5mg/kg efzofitimod demonstrated: - **A reduction in corticosteroid use**, exceeding placebo. - Statistically significant and clinically meaningful **improvements in KSQ-Lung and SGRQ**. - Dose-dependent reduction in **inflammatory biomarkers** like IP-10 and TNF-α. These multi-domain improvements—objective, subjective, and biological—form a compelling foundation for the Phase 3 program. **Bottom Line:** It’s fair to be cautious—biotech investing demands it. But the claim that efzofitimod’s Phase 3 readout is likely to be “ambiguous” underestimates both the **trial’s power** and the **biological signal** already observed. EFZO-FIT is unusually well-constructed for a rare disease trial, and efzofitimod’s selective NRP2 modulation represents a truly novel mechanism supported by translational science from Scripps, Boston Children’s, and aTyr’s mechanistic publications. And let’s not forget: the institutional ownership base has grown dramatically over the past two quarters, and now includes **FMR, Vanguard, Point72, Goldman Sachs, BlackRock, Adage, Alyeska, and Logos**—not typical behavior for a “maybe” readout. Their analysts would’ve already weighed all of these exact risks. $ATYR
ATYR. Trust. 
Thanks for taking the time to write this. There will never be a sure fire win in BioTech. The reason I'm invested heavily is because I'm leaning towards the probability of success as indicated by your analysis. Of course, you're analysis is a lot more detailed than what I did. Just to anyone looking at this thread, approach ATYR with a healthy amount of skepticism. In fact try to find as many negatives as you can. You're looking at a stock that can go +300% to -80% within a day. So you need to be 100% sure why you're in this stock. Good luck and thank you for the work you're putting in here and in StockTwits.
Am I doing something wrong? I’ve tried posting a few times about ATYR but my posts never go live. Would appreciate any feedback on why the bots are automatically removing my posts. Thx
Thanks for your thoughtful reply—and first off, respect for being “real hard” in. You clearly care enough to think critically, which I rate highly. Let’s unpack your points systematically, because they’re valid to raise—but I think there’s a stronger case than you might realise once we zoom in on the specifics. 1. “Retail hasn’t arrived” — Is that just narrative? This isn’t just a throwaway line—it’s based on hard signals in the data: • Daily volume averages ~100–200k shares—for a float of ~32.7M, that’s thin. • The price rarely holds >$4.50, which sits right beneath major call gamma clusters (especially for 5/17 and 6/21 expiries). • Reddit, StockTwits, and FinTwit coverage remains nearly non-existent relative to microcaps with similar setups. This is not a GME-style meme crowd yet. • No major breakout candle since late 2023. Price action still governed by low-liquidity grinding. That’s what “retail hasn’t arrived” means. It’s not about absolutes—it’s about relative awareness and inflow. This still trades like a stock no one is watching, despite the late-stage asset and real pipeline. 2. “Market makers are suppressing price” — or just natural price mechanics? Fair to question, and to be clear: we’re not alleging conspiracy. But there are signs of mechanical pinning behavior that often coincide with institutional accumulation phases. • Gamma exposure (GEX) has been persistently negative across key strikes ($4.00, $5.00, $7.50), indicating dealers are short gamma and need to sell into strength as price rises. • Call volume and OI in deep OTM strikes (5–10–15) have increased, with LEAPS disproportionately stacked. This asymmetry mechanically pressures price toward max pain until hedging dynamics flip. • Dark pool volume remains >50% most days, based on FINRA TRF and off-exchange prints. That suggests algo-mediated accumulation or suppression, not natural retail trading. These aren’t accusations—they’re structural facts of how illiquid options-driven stocks behave when institutions are building exposure and market makers are net short gamma. 3. “Gamma squeeze impact is overhyped in small biotechs” True if the float is large and options OI is low. But in this case: • Short interest is 12.23% of float, with ~10.7 days to cover . • Options OI at May/June 5, 7.5, 10 strikes is significant relative to ADV. • Gamma exposure flips around $5, which coincides with LEAP hedging thresholds and dark pool volume drops. When price starts moving with volume, dealers must delta hedge, which can mechanically escalate the move—even in small caps. See ARDS (2021), RLAY, and VSTM for examples of micro-cap biotechs with small floats that moved violently due to options-based dislocations. 4. “You glossed over the risks” Absolutely fair. Let’s confront them: a) Phase 3 failure risk Always real. But efzofitimod has: • Peer-reviewed Phase 1b/2a results: +180mL FVC (p=0.035), 85% relapse reduction • Clean safety, no deaths, and no withdrawals due to adverse events • A running Expanded Access Program (EAP) before readout—a rare vote of confidence from FDA and clinical partners • Mechanistic validation published in Science Translational Medicine: NRP2 binds inflammatory macrophages and reprograms them to pro-resolving states This isn’t a black-box biotech praying for a signal. It’s a de-risked candidate with multiple converging confidence signals. b) Funding / dilution ATYR has adequate runway through Phase 3 readout. Japan progress payments come into play too. More funding will come—but after the value-inflecting catalyst, not before. Also worth noting: insiders are buying. Director Jane Gross purchased 3,750 shares on March 17, 2025—bringing her total to 9,750. Not a large amount in dollars, but symbolically important during a pre-readout period . c) Adoption risk Pulmonary sarcoidosis is a high-unmet-need market. The standard of care is steroids, which are toxic and non-curative. There is no FDA-approved disease-modifying therapy. If efzofitimod gets approved with even modest payer support, uptake could be swift—especially since many patients are already on it via EAP or compassionate use channels. 5. So what’s the core disagreement? It comes down to how you weigh the coiled structure: • Float is small (~32.7M), with >12% short and heavy institutional ownership • Valuation is absurdly low ($300M) vs $500M–$700M rev potential in just sarcoidosis • Scientific, regulatory, and market signals are all aligning • Options chain and volume profile reflect a classic pre-breakout structure This isn’t hype—it’s an asymmetric setup where fundamentals, market structure, and psychology are beginning to converge. Happy to debate any of this, but I hope the added facts help clarify where I’m coming from. There’s a whole lot more that I could add. I respect skepticism—especially in biotech. But this setup is rare, and all the ingredients are in place. Let’s see what happens.
Fair concern—biotech’s burned a lot of people. But here’s why $ATYR is different: • $94M+ in cash post-ATM • Explicitly stated runway: “Through at least one year post Phase 3 readout” • No need to raise before data. No pressure immediately after. Add to that: • $155M+ in milestone potential from Japanese partner Kyorin (non-dilutive) • CEO’s recent tone (in private & public): zero desperation, high control • Strategic interest building ahead of readout • Backed by RA Capital, Deep Track, Renaissance Tech—not the kind of funds who tolerate dilution risk pre-catalyst If the trial hits, they raise on strength—or don’t need to raise at all. 10K+ @ $3.01
Personally, I haven’t really been daytrading since the tariffs were introduced. My portfolio right now is 90% VOO. With the remaining 10% I’m swing trading SCPH and ATYR. I managed to average down SCPH to $2.03 during the most recent dip. I’ll probably sell soon. I’m sitting at around $2.60 with ATYR. Still deciding whether to sell now and buy back in on a pullback, or hold until Q3.
I’m loaded up on ATYR. Pharma stock with positive FDA guidance, ready to jump with the release of Phase III data in Q3. Pretty well insulated from tariffs and recession. I think it will hit $20-25 (7-8x) by end of year.
Been swinging this puppy and SCPH for a while now. They both coast between $2 and $3. Closer to Q3 I’ll probably go large on ATYR in anticipation of their Phase 3 trial results.
Check ATYR (aTYr pharma), Analyst avg price target is $18 (12analysts) and has good market cap as well
There are always people who have to sell stocks for like personal reasons. Fundamentals didn’t change and so there is no good reason why anyone would sell. If the stock should drop to $1, while the fundamentals still haven’t changed…I‘m becoming as greedy as Buffet would want me to become in that scenario and squeeze the very last penny out of my piggy bank to get as many shares as I could! Pharma tariffs won’t affect out play, since A) tariffs are slapped on imported drugs and ATYR is a US domestic company B) retaliatory tariffs won’t affect our play either. **We are betting on a „sell the news event“ of Efzofitimod successfully completing phase 3.** That comes way before mass manufacturing, distributing *or exporting* it to countries outside the US.
Where do u think ATYR will go to? Will it approach 1 Dollar? Will it go under 1 Dollar? Trump just announced or will announce in the near future pharma tariffs.
ATYR is easy money if you swing trade it right now. It bounces between $2 and $4 constantly. Come Q3 it should jump with their Phase 3 trial update.
-WWR -CANF -ATYR Not financial advice
all in ATYR $40 upside by quarter 4
ATYR… it’s not on my watch list though… I own 30K worth of it
I like biotech. It’s insulated. ATYR is my baby
I’m also in ATYR , hace you heard of it?
ATYR earnings tmr up $700 today woohoo 🙌
$ATYR and $QBTS earnings today. Still bag holding $CTM, $BBAI, $MNMD, $IBIO
ATYR phase 3 trials safety protocol is good and updates at earnings call Thursday
got 2,000 shares in ATYR bag holding 10x upside current price is $3.40. https://preview.redd.it/izr1k8xjrone1.jpeg?width=1179&format=pjpg&auto=webp&s=b7275ff643ee5c6c1c48054318c61ec53c574a92
Did anyone say YOLO? I have been mainly cashing out on my portfolio as well. I still like to keep up a bet or two, one of these bets is ATYR. It’s a low risk strategy. Buffet‘s famous piece of advice is also not about him buying cheap vs expensive stocks, but about market cycles. In the current situation I view it as super valid and I‘ll follow it, averaging down on what I believe in. Just two inspirations that don’t contradict each other.
ATYR is 60%+ institutional investors on a 200m market cap. Anytime you see these whales exiting or entering their positions you're going to see volatile price action. It's still up 70% from 3 months ago. Not surprising to see long time holders booking gains or cycling in or out.
I am not recommending anything, I am saying its a gamble on phase 3 data and you cannot say if ATYR is over or under valued until then, so it is a gamble, since you got in for phase 3 data it does not matter if the stock drops or not, you are holding for the result and possible upside to double digit. If you are very convinced based on your research or gut feeling you can average down slowly as it falls due to market condition. But do not fool yourself thinking its undervalued now because its down 20% since highs. you cannot make any opinion on the valuation until the data is out.
Yes, Phase 3 results in September are the most important catalyst. For a stock with an **avg analysts rating of about $19 per share**, based on a company that's very close to entering a **$500B market without competition**. Will it happen for certain? Of course not. Does it appear very likely to me? Hell yes! My current average is $3.60, expecting a 5-bagger ($3.60 to $19) return. Everything that's lower than that is a SALE to me, because it will function as a **Margin Of Safety** in the (possible, yet unlikely) case that Efzofitimod bombs it's Phase 3. Another viewpoint is this: The stock didn't lose value because of ATYR. It lost value because of overall market sentiment induced by tariffs. **If you believed in ATYR before tariffs, you should feel like it's on sale now** because OUTSIDE forces (macro environment) made each share of the company cheaper than it was yesterday! Comparing book value to a biotech startup is obviously not leading anywhere, as you said yourself. A sale should still be recognized as a sale, though.
Fundamentals didn’t change. Market sentiment did. People are withdrawing their money to park it on the sidelines. ATYR is on sale and I‘ll bottom feed like a lunatic! Buffet told me to be greedy when others are fearful. Cheers!
Anyone else here investing in $MIST or $ATYR? They’re not moving too much right now, but both are biotech stocks that have nice forecasting around them and drug/trial results to report this year.
[https://www.marketbeat.com/stocks/NASDAQ/ATYR/forecast/](https://www.marketbeat.com/stocks/NASDAQ/ATYR/forecast/)
I was referring to the specific day when ATYR was down 11%. But I'm not against ATYR -- I just wouldn't go out of my way to highlight a stock that has already jumped 130% in such a short period. That's it.
ATYR is a long play. It’ll fly in 25Q3.
ATYR. Sell after the phase 3 trial in August/September
I'm not talking about the general risk in biotech -- of course, there's always a risk. I'm just saying it would have been much better to discuss this name a few months ago, before it jumped 130%. Those high-flyers are usually the first to tumble hard, as you saw today (ATYR -11%).
need ATYR to drop below 4 again and i’m loading up
ATYR already jumped 130% over the past 6 months, so the risk-reward now is less attractive.
Made $2.1M on ACHR. Rolled profits into ATYR
Wtf, the reports for ATYR are all over the place.. "ATYR is currently among a group of 279 stocks awarded or lowest score of 1.". And yet remains a buy. 1 year returns are 87.6%, but 5 year returns are -10.2%, with a -78% return on equity. I'm not even sure what to make of these numbers. 🤪
Been planning all night on getting into ATYR this morning when the market opens; hoping for a *small* dip right at open so I’m not buying at peak
That was the old ticker. They changed to ATYR last summer